2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Abstract Number: 16

Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Abstract Number: 17

Anti-endothelial cell antibodies in juvenile dermatomyositis
Abstract Number: 18

Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen
Abstract Number: 19

The Lymphocyte Repertoire in Juvenile Dermatomyositis
Abstract Number: 20

Enthesitis-Related Arthritis: Non-Peripheral Pattern is Associated with an Expansion of Peripheral Th17 Populations
Abstract Number: 21

Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Abstract Number: 22

Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis
Abstract Number: 23

Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Abstract Number: 24

Development and Implementation of a “Data-In-Once” Model for a Pediatric Rheumatology Learning Health System
Abstract Number: 25

Reliability of the Physician Global Assessment Scores for Determination of Disease Activity Status within the Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 26

Gray Matter Volume Loss in Youth with SLE
Abstract Number: 27

Assessing the Safety of Kidney Biopsies Performed on Childhood-onset Systemic Lupus Erythmatosus Patients
Abstract Number: 28

Dyslipidemia in Juvenile Dermatomyositis
Abstract Number: 29

Spinal Cord Inflammation in Children with Small Vessel Primary CNS Vasculitis
Abstract Number: 30

Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].